Divis to invest Rs 2,000 crore to expand peptide synthesis capacity
New Delhi: Hyderabad-based contract manufacturing pharma giant Divis Laboratories has decided to expand its peptide synthesis manufacturing capacity. The company has announced that it wants to set up new solid phase peptide synthesis (SPPS) lines in the wake of increasing global demand for peptide-based drugs. He said that taking into account the current RFs, it will require an investment of around Rs 2,000 crore, which is 20 percent.
You Might Also Like
-
Gold prices are gradually declining in the wake of international geopolitical factors. They also...
-
Mumbai: Indian stock market indices gained heavily for the second consecutive day. In Wednesday's...
Leave A Comment
Comments